Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to RRP1B" (ENSG00000303490, LOC124905030) is an annotated noncoding RNA predicted to be transcribed in the antisense orientation relative to the protein-coding gene Ribosomal RNA Processing 1B (RRP1B). There is no experimental evidence defining its expression, function, protein product, biological pathways, or involvement in human disease. It is not recognized as a therapeutic target, receptor, enzyme, or biomarker in major gene, protein, or drug databases. Most characterized functions and any therapeutic interest pertain to RRP1B itself, not its antisense transcripts[1][3][4]. If your intent is to investigate RRP1B as a therapeutic target or molecular entity, refer instead to "Ribosomal RNA processing 1B" for structured information[1][3][4]. This antisense transcript remains a poorly characterized genomic annotation with unknown biological or clinical significance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to RRP1B.